• Cosentyx Gains Positive CHMP Opinion for Pediatric Psoriasis americanpharmaceuticalreview
    July 08, 2020
    Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and ...
PharmaSources Customer Service